Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children’s Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force
Holly Pacenta(Children's Hospital Colorado), Theodore W. Laetsch(Children's Hospital of Philadelphia), Charles Keller(Children's Cancer Therapy Development Institute), Stephen X. Skapek(Duke University), William H. Meyer(Lawrence Livermore National Laboratory), Wendy Allen‐Rhoades(Mayo Clinic), Javed Khan(Kent State University), Christine M. Heske(National Institutes of Health), Brian Turpin(Cincinnati Children's Hospital Medical Center), Corinne M. Linardic(Duke University), Pooja Hingorani(Center for Cancer and Blood Disorders), Michael D. Deel(Duke University), Leo Mascarenhas(University of Southern California), Peter J. Houghton(The University of Texas at San Antonio Health Science Center), Eleanor Y. Chen(University of Washington), Douglas J. Harrison(The University of Texas MD Anderson Cancer Center), Douglas S. Hawkins(Seattle Children's Hospital), James F. Amatruda(University of Southern California), David M. Langenau(Massachusetts General Hospital), Elizabeth Stewart(St. Jude Children's Research Hospital), Jack F. Shern(National Institutes of Health)
Cited by 28
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks
|Nature Medicine|2001|2.7k
Comprehensive Analysis of Hypermutation in Human Cancer
|Cell|2017|795
Comprehensive Genomic Analysis of Rhabdomyosarcoma Reveals a Landscape of Alterations Affecting a Common Genetic Axis in Fusion-Positive and Fusion-Negative Tumors
|Cancer Discovery|2014|789
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
|European Journal of Cancer|2019|724